Company Update (NYSE:BMY): High Stakes Intrigue In Hep C: Bristol-Myers Vs. Gilead

January 22, 2014 at 15:47 PM EST

[at Seeking Alpha] – Gilead’s ( GILD ) reluctance to marry its Hep C drug Sovaldi with Bristol-Myers Squibb’s ( BMY ) daclatasvir forced Bristol to take evasive action. Bristol applied to the . . . → Read More: Company Update (NYSE:BMY): High Stakes Intrigue In Hep C: Bristol-Myers Vs. Gilead Similar Articles: Company Update (NASDAQ:GILD): High Stakes Intrigue In Hep C: Bristol-Myers Vs. Gilead Stock Update: Biogen Idec Inc. (NASDAQ:BIIB) – [video] Biogen CEO: More products, company is focused Boeingâ€™s Double Top: Will the company continue to soar?

Bristol-Myers Squibb Company (NYSE:BMY) [at Seeking Alpha] – Gilead’s ( GILD ) reluctance to marry its Hep C drug Sovaldi with Bristol-Myers Squibb’s ( BMY ) daclatasvir forced Bristol to take evasive action. Bristol applied to the European Union for approval of …
Read more on … [visit site to read more]